NCT05361421

Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial

Name: Clinical Trial NCT05361421
Creator: Yonsei University
Keywords: Cardiovascular Disease, Intensive targeting group, Phase 4, drug, clinical trial, South Korea

Yonsei University·Phase 4·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Cardiovascular Disease
Drug/Device/Intervention: Intensive targeting group
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Yonsei University
Location: Seoul, South Korea

Timeline & enrollment

Phase: Phase 4
Start date: Sep 14, 2022
End date: Oct 01, 2027
Enrollment: 1200 participants

Primary outcome

Clinical efficacy of intensive lipid-lowering therapy

Summary

Although there have been studies regarding intensive lowering of low-density lipoprotein (LDL)-cholesterol with high intensity statins in patients with cardiovascular disease, elderly patients were either excluded or accounted only a small portion of study subjects. Therefore, this study sought to compare the clinical outcomes according to the LDL-cholesterol therapy targeting (intensive targeting [LDL-cholesterol 55mg/dL] vs. conventional therapy [moderate intensity statin therapy]) in elderly patients with ≥75 years and documented cardiovascular disease.

ICD-10 classifications

Cardiovascular disease, unspecifiedHypertensive heart diseaseHeart disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart disease

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05361421
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05361421 through Pure Global AI's free database. This Phase 4 trial is sponsored by Yonsei University and is currently Recruiting. The study focuses on Cardiovascular Disease. Target enrollment is 1200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.